This article is more than 5 years old. Information may no longer be current.

MP29-02 appears effective in reducing upper airway eosinophilic infiltration

Intranasal formulation of azelastine hydrochloride and fluticasone propionate has demonstrated clinical effects in allergic rhinitis compared with corticosteroids and antihistamines in monotherapy, according to research presented at the Experimental Rhinology and Immunology of the Nose Symposium in Stockholm.

Researchers incubated peripheral blood eosinophils for 4 days with decreasing dilutions of the azelastine hydrochloride (AZ) and fluticasone propionate (FP) combination therapy, equivalent dilutions of FP, and AZ alone before the addition of epithelial cell culture media (ECM) from nasal mucosa.

During the third day of incubation, the AZ and FP combination therapy inhibited eosinophil survival induced by ECM from dilution (standard error of the mean (SEM) = 13.8%, n = 6) to dilution (SEM = 58.8%, n = 6), compared with ECM.

The inhibitory effect on eosinophil survival induced by the combination therapy at 1:10² dilution was stronger (P < .05) than that induced by FP alone (SEM = 36.7%) or AZ alone (SEM = 70.3%) at similar dilutions.

Reference:

Rocca-Ferrer J, et al. Abstract P009. Presented at: Experimental Rhinology and Immunology of the Nose Symposium; March 19-21, 2015; Stockholm, Sweden.

Disclosure: Healio.com/Allergy was unable to determine relevant financial disclosures at this time.